共 50 条
- [41] Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial DIABETES OBESITY & METABOLISM, 2024, 26 (02): : 758 - 762